Vivesto AB
STO:VIVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vivesto AB
STO:VIVE
|
SE |
|
M
|
Molecure SA
WSE:MOC
|
PL |
|
T
|
Tietoevry Oyj
OMXH:TIETO
|
FI |
|
Indeks Bilgisayar Sistemleri Muhendislik Sanayi ve Ticaret AS
IST:INDES.E
|
TR |
|
M
|
Mount Burgess Mining NL
ASX:MTB
|
AU |
|
Manila Water Company Inc
OTC:MWTCF
|
PH |
Vivesto AB
Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Oasmia Pharmaceutical AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
